SU 6656 (SU-6656) is a novel, potent and selective Src family kinase (Src, Yes, Lyn, and Fyn) inhibitor with potential antineoplastic activity. It inhibits Src, Yes, Lyn, and Fyn with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM respectively. SU6656 modulates CTGF (connective tissue growth factor) expression in an ERK-dependent manner. SU6656 induces caspase-independent cell death in FRO anaplastic thyroid carcinoma cells and therapeutic synergy in human synovial sarcoma growth, invasion and angiogenesis in vivo. In NIH 3T3 cell, SU6656 inhibits PDGF-/Src-driven mitogenesis and PDGF-stimulated c-Myc induction.
Physicochemical Properties
| Molecular Formula | C19H21N3O3S | |
| Molecular Weight | 371.45 | |
| Exact Mass | 371.13 | |
| CAS # | 330161-87-0 | |
| Related CAS # |
|
|
| PubChem CID | 5312137 | |
| Appearance | Yellow to orange solid powder | |
| Density | 1.4±0.1 g/cm3 | |
| Index of Refraction | 1.657 | |
| LogP | 3.46 | |
| Hydrogen Bond Donor Count | 2 | |
| Hydrogen Bond Acceptor Count | 4 | |
| Rotatable Bond Count | 3 | |
| Heavy Atom Count | 26 | |
| Complexity | 697 | |
| Defined Atom Stereocenter Count | 0 | |
| SMILES | CN(C)S(=O)(=O)C1=CC\2=C(C=C1)NC(=O)/C2=C\C3=CC4=C(N3)CCCC4 |
|
| InChi Key | LOGJQOUIVKBFGH-YBEGLDIGSA-N | |
| InChi Code | InChI=1S/C19H21N3O3S/c1-22(2)26(24,25)14-7-8-18-15(11-14)16(19(23)21-18)10-13-9-12-5-3-4-6-17(12)20-13/h7-11,20H,3-6H2,1-2H3,(H,21,23)/b16-10- | |
| Chemical Name | (Z)-N,N-dimethyl-2-oxo-3-((4,5,6,7-tetrahydro-1H-indol-2-yl)methylene)indoline-5-sulfonamide | |
| Synonyms | SU 6656; SU-6656; SU6656; | |
| HS Tariff Code | 2934.99.9001 | |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | In HNSCC cells, SU6656 lowers the phosphorylation of Src family kinase (SFK) [2]. |
| ln Vivo | Fall time increase caused by ischemia postconditioning (IPoCo) is greatly reduced by SU6656 (2-4 mg/kg; i.p.; once) [5]. |
| Animal Protocol |
Animal/Disease Models: Swiss albino male mice[5] Doses: 2, 4 mg/kg Route of Administration: intraperitoneal (ip)injection; once Experimental Results: Dramatically diminished IPoCo mediated increase in fall down time. |
| References |
[1]. SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling. Mol Cell Biol. 2000 Dec;20(23):9018-27. [2]. Elevated Src family kinase activity stabilizes E-cadherin-based junctions and collective movement of head and neck squamous cell carcinomas. Oncotarget. 2014 Dec 26. [3]. Divergent signaling pathways cooperatively regulate TGFβ induction of cysteine-rich protein 2 in vascular smooth muscle cells. Cell Commun Signal. 2014 Mar 28;12:22. [4]. Inhibition of mTORC1 by SU6656, the selective Src kinase inhibitor, is not accompanied by activation of Akt/PKB signalling in melanoma cells. Folia Biol (Praha). 2013;59(4):162-7. [5]. Pharmacological investigations on possible role of Src kinases in neuroprotective mechanism of ischemic postconditioning in mice. Int J Neurosci. 2014 Oct;124(10):777-86. [6]. Antitumor effects of immunotoxins are enhanced by lowering HCK or treatment with SRC kinase inhibitors. Mol Cancer Ther. 2014 Jan;13(1):82-9. |
Solubility Data
| Solubility (In Vitro) |
|
|||
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2 mg/mL (5.38 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 10% DMSO+dd H2O: 16mg/mL (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6922 mL | 13.4608 mL | 26.9215 mL | |
| 5 mM | 0.5384 mL | 2.6922 mL | 5.3843 mL | |
| 10 mM | 0.2692 mL | 1.3461 mL | 2.6922 mL |